ADXN
Addex Therapeutics LtdHealthcare · $4M market cap
Verdict
We can't put a fair value on ADXN right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ADXN
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 2, 2026: no open-market purchases and 37 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Dyer Timothy Mark
CHIEF EXECUTIVE OFFICER · 2026-09-02
Award
$108K
Dyer Timothy Mark
CHIEF EXECUTIVE OFFICER · 2026-09-02
D-Return
$209K
Dyer Timothy Mark
CHIEF EXECUTIVE OFFICER · 2026-09-02
Award
16,413,787 shares
Dyer Timothy Mark
CHIEF EXECUTIVE OFFICER · 2026-09-02
D-Return
16,413,787 shares
Hill Raymond George
director · 2026-09-02
Award
$9K
Show all 37 other filingsShow fewer
Hill Raymond George
director · 2026-09-02
D-Return
$17K
Hill Raymond George
director · 2026-09-02
Award
1,365,532 shares
Hill Raymond George
director · 2026-09-02
D-Return
1,365,532 shares
Lawton Vincent Michael
director · 2026-09-02
Award
$16K
Lawton Vincent Michael
director · 2026-09-02
D-Return
$31K
Lawton Vincent Michael
director · 2026-09-02
Award
2,507,487 shares
Lawton Vincent Michael
director · 2026-09-02
D-Return
2,507,487 shares
Manke Isaac
director · 2026-09-02
Award
$2K
Manke Isaac
director · 2026-09-02
D-Return
$3K
Manke Isaac
director · 2026-09-02
Award
219,561 shares
Manke Isaac
director · 2026-09-02
D-Return
219,561 shares
Mills Roger
CHIEF MEDICAL OFFICER · 2026-09-02
Award
$2K
Mills Roger
CHIEF MEDICAL OFFICER · 2026-09-02
D-Return
$3K
Mills Roger
CHIEF MEDICAL OFFICER · 2026-09-02
Award
392,837 shares
Mills Roger
CHIEF MEDICAL OFFICER · 2026-09-02
D-Return
392,837 shares
Nunn Jason Raleigh
director · 2026-09-02
Award
$2K
Nunn Jason Raleigh
director · 2026-09-02
D-Return
$3K
Nunn Jason Raleigh
director · 2026-09-02
Award
219,561 shares
Nunn Jason Raleigh
director · 2026-09-02
D-Return
219,561 shares
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE · 2026-09-02
Award
$6K
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE · 2026-09-02
D-Return
$12K
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE · 2026-09-02
Award
306,765 shares
Kalinichev Mikhail
HEAD OF TRANSLATIONAL SCIENCE · 2026-09-02
D-Return
306,765 shares
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$6K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$11K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$14K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$10K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$5K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$2K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$10K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
Award
$3K
Teyssedou Lenaic Nathanael
PRINCIPAL ACCOUNTING OFFICER · 2026-09-02
D-Return
$6K
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works